Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta‐human chorionic gonadotropin and pregnancy‐associated plasma protein‐A

6 May 2008

Abstract excerpt

OBJECTIVES: To derive a model and examine the performance of first-trimester combined screening by maternal age, fetal nuchal translucency (NT) thickness and maternal serum free beta-human chorionic gonadotropin (beta-hCG) and pregnancy-associated plasma protein-A (PAPP-A). METHODS: Prospective combined screening for trisomy 21 was carried out at 11 + 0 to 13 + 6 weeks in 56,771 singleton pregnancies, including...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Assisted Reproductive Technology and Twin Pregnancy
Share to Gestational Trophoblastic Disease Studies
Share to Prenatal Screening and Diagnostics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 18461550
DOI: 10.1002/uog.5331

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta‐human chorionic gonadotropin and pregnancy‐associated plasma protein‐APMID 18461550Read ↗

Screening for trisomy 18 by maternal age, fetal nuchal translucency, free β‐human chorionic gonadotropin and pregnancy‐associated plasma protein‐ASemantic proximity Read ↗

Prospective validation of first‐trimester combined screening for trisomy 21Semantic proximity Read ↗

First‐trimester combined screening for trisomy 21 at 7–14 weeks' gestationSemantic proximity Read ↗

Accuracy of first‐trimester combined test in screening for trisomies 21, 18 and 13Semantic proximity Read ↗

UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group.Semantic proximity Read ↗

First‐trimester screening for trisomy 21 by free beta‐human chorionic gonadotropin and pregnancy‐associated plasma protein‐A: impact of maternal and pregnancy characteristicsSemantic proximity Read ↗

A screening program for trisomy 21 at 10–14 weeks using fetal nuchal translucency, maternal serum free β‐human chorionic gonadotropin and pregnancy‐associated plasma protein‐ASemantic proximity Read ↗

A unified approach to risk assessment for fetal aneuploidiesSemantic proximity Read ↗

Maternal serum pregnancy‐associated plasma protein a and fetal nuchal translucency thickness for the prediction of fetal trisomies in early pregnancySemantic proximity Read ↗

First‐trimester screening for trisomy 21 combining biochemistry and ultrasound at individually optimal gestational ages. An interventional studySemantic proximity Read ↗

First-Trimester Screening for Trisomies 21, 18 and 13 by Ultrasound and Biochemical TestingSemantic proximity Read ↗

A reassessment of biochemical marker distributions in trisomy 21‐affected and unaffected twin pregnancies in the first trimesterSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.